Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 27, 2008
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based healthcare practitioners in North America and Europe. The company serves over 575,000 customers, including dental, medical, and animal health practitioners. Operations are conducted through two reportable segments: Healthcare Distribution (dental, medical, animal health, and international) and Technology (practice management software and value-added services).
Key Financial Metrics
| Metric | 2008 (in thousands) | 2007 (in thousands) |
|---|---|---|
| Net Sales | $6,394,874 | $5,904,416 |
| Gross Profit | $1,884,538 | $1,716,574 |
| Gross Margin | 29.5% | 29.1% |
| Operating Income | $419,603 | $387,939 |
| Net Income | $243,143 | $215,173 |
| Diluted EPS | $2.67 | $2.36 |
| Operating Cash Flow | $384,649 | $270,211 |
| Total Debt | $427,987 | $456,570 |
| Cash and Equivalents | $369,570 | $247,590 |
| Working Capital | $882,607 | $908,160 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.3% to $6.39 billion, driven by a 25.5% increase in International sales (primarily due to acquisitions) and a 23.8% increase in Technology sales. Dental sales grew 4.8%, while Medical sales declined 7.2% due to the strategic exit from low-margin pharmaceutical products ($153 million in 2007 sales).
- Profitability: Operating income rose 8.2% to $419.6 million. Net income increased 13.0% to $243.1 million. Gross margin improved slightly to 29.5%.
- Restructuring: The company incurred $23.2 million in one-time restructuring costs in 2008 (none in 2007) related to the elimination of approximately 300 positions and facility closures. Expected annual savings are $24.0 million to $27.0 million.
- Discontinued Operations: The company recorded a loss of $7.9 million from discontinued operations in 2008, primarily due to an $11.2 million impairment charge related to the exit from its wholesale ultrasound business.
- Debt Reduction: Total debt decreased by approximately $28.6 million to $428.0 million, aided by the repayment of senior notes and reduced borrowing under credit lines.
Guidance, Outlook, and Risks
- Economic Outlook: Management expects no improvement in the economic environment during 2009 and anticipates slower growth rates for demand for products and services due to recessionary conditions.
- Restructuring Impact: Remaining restructuring costs of $1.0 million to $3.0 million are expected to be recorded in the first quarter of 2009.
- Capital Expenditures: The company plans to invest approximately $40.0 million to $50.0 million in 2009 for capital projects to modernize facilities and computer systems.
- Liquidity and Credit: The company maintains a $400 million revolving credit facility (with no borrowings outstanding as of year-end) and $369.6 million in cash. However, $29.0 million of investments in Auction-Rate Securities (ARS) are illiquid due to market failures, though the company believes these will not impact operations.
- Key Risks:
- Financial Market Disruptions: Potential inability of customers to pay or vendors to supply products due to credit tightening.
- Regulatory Changes: Ongoing scrutiny of healthcare fraud, drug pedigree requirements, and potential healthcare reform.
- Competition: Intense competition from other distributors and manufacturers selling directly to end-users.
- Supply Chain: Dependence on third-party manufacturers for substantially all products.
Investor Verification Checklist
- Restructuring Execution: Verify the realization of the projected $24.0 million to $27.0 million in annual cost savings from the 2008 restructuring plan.
- Medical Segment Recovery: Monitor the Medical segment's performance post-exit of low-margin pharmaceuticals to ensure the strategic shift improves long-term margins.
- ARS Liquidity: Track the status of the $29.0 million in illiquid Auction-Rate Securities and any potential impairment charges if market conditions worsen.
- Debt Maturities: Confirm refinancing plans for $156.4 million in debt maturing in 2009, including $130 million in senior notes.
- Acquisition Integration: Assess the integration of significant 2008 acquisitions (e.g., DNA, Medka, Noviko, Software of Excellence) and their contribution to organic growth.